Pharmacy Medical News about tyrosine kinase inhibitors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical pharmacokinetics of tyrosine kinase inhibitors
Cancer Treatment Reviews, 09/17/09

van Erp NP et al. – In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over–expressed in cancer tissues. By understanding the pharmacokinetic profile of these drugs and their similarities, factors that influence drug exposure will be better recognized and this knowledge may be used to limit sub– or supra–therapeutic drug exposure.

<< Previous
FDA actions in brief, September 2009 (Saphris, Tracleer, Livalo,...

Next >>
Head-to-head trial demonstrates Viramune®’s similar efficacy and...

Eruptive Keratoacanthoma-Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors
Dermatologic Surgery, 11/17/09 Relevance Score: 80%

Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Haematologica, 10/21/09 Relevance Score: 79%

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09 Relevance Score: 79%

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09 Relevance Score: 79%

Small, Mobile Fc[epsilon]RI Receptor Aggregates Are Signaling Competent
Immunity, 10/01/09 Relevance Score: 79%